Something is going on here. Is this a sign?

Exact Sciences Corp (EXAS): Kevin T Conroy , President and CEO of Exact Sciences Corp sold 11,386 shares on Jul 27, 2015. The Insider selling transaction was disclosed on Jul 28, 2015 to the Securities and Exchange Commission. The shares were sold at $24.04 per share for a total value of $273,719.44.

On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Securities and Exchange Commission has divulged that Lidgard Graham Peter, Director of Exact Sciences Corp, had unloaded 3,938 shares at an average price of $23.44 in a transaction dated on February 26, 2015. The total value of the transaction was worth $92,307.EXACT Sciences Corporation (NASDAQ:EXAS) should head towards $29 per share according to 10 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $12 per share. The higher price estimate target is at $37 according to the Analysts.

EXACT Sciences Corporation (NASDAQ:EXAS) : On Monday heightened volatility was witnessed in EXACT Sciences Corporation (NASDAQ:EXAS) which led to swings in the share price. The shares opened for trading at $24.03 and hit $24.16 on the upside , eventually ending the session at $24.15, with a gain of 0.04% or 0.01 points. The heightened volatility saw the trading volume jump to 1,443,169 shares. The 52-week high of the share price is $32.85 and the company has a market cap of $2,316 million. The 52-week low of the share price is at $15.12 .

The company shares have rallied 75.64% in the past 52 Weeks. On June 25, 2015 The shares registered one year high of $32.85 and one year low was seen on August 1, 2014 at $15.12. The 50-day moving average is $28.19 and the 200 day moving average is recorded at $25.51. S&P 500 has rallied 7.62% during the last 52-weeks.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company’s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The Company’s Cologuard test includes methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed.